Dyax Corp.
55 Network Drive
Burlington
Massachusetts
01803
United States
Tel: 617-225-2500
Fax: 617-225-2501
Website: http://www.dyax.com/
Email: ir@dyax.com
About Dyax Corp.
Founded in 1995, Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s key areas of focus are the KALBITOR® (ecallantide) business and the Angioedema Portfolio, as well as the Licensing and Funded Research Program (LFRP). Dyax discovered and developed KALBITOR on its own and, since February 2010, the Company has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside of the United States, the Company has established partnerships to obtain regulatory approval for and commercialize KALBITOR in certain markets and is evaluating opportunities in others. Currently, Dyax has collaboration agreements for regions including Europe, Japan, Russia, the Middle East, Australia and New Zealand. Dyax is also exploring other potential indications for KALBITOR, either alone or through collaborations.The Company is expanding its portfolio for the treatment of angioedemas by identifying diagnostic strategies to assist in the differentiation between histamine-mediated and plasma kallikrein (bradykinin) mediated (PKM) angioedema, and developing a fully human monoclonal antibody inhibitor of plasma kallikrein, DX-2930, which could be a candidate to prophylactically treat PKM angioedemas. KALBITOR and DX-2930 were identified using Dyax’s patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 11 product candidates in various stages of clinical development, including three in Phase 3 trials.
Dyax is headquartered in Burlington, Massachusetts. For online information about Dyax Corp., please visit www.dyax.com.
338 articles about Dyax Corp.
-
Dyax Corp. Announces The Appointment Of Peggy Berry As Senior Vice President Of Quality And Regulatory Affairs
5/24/2006
-
Dyax Corp. And ICOS Corporation Enter Into License Agreement For Discovery Of Therapeutic Antibodies
5/22/2006
-
US FDA Seeks More Data On Dyax Corp. Swelling Drug
5/16/2006
-
Dyax Corp. To Present At Deutsche Bank Health Care Conference
4/28/2006
-
Dyax Corp. Announces First Quarter Financial Results
4/26/2006
-
Dyax Corp. Files Shelf Registration Statement
4/17/2006
-
Dyax Corp. Announces $30 Million Financing
3/9/2006
-
Dyax Corp. Release: Positive Topline Results From Phase II Trial With DX-88 For The Treatment Of Hereditary Angioedema
3/6/2006
-
Dyax Corp. To Host Fourth Quarter And Year End 2005 Earnings Call And Webcast
2/16/2006
-
Dyax Corp. To Present At Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/13/2006
-
Dyax Corp. Issued Fifth U.S. Patent In Its Phage Display Patent Portfolio
1/10/2006
-
Dyax Corp. To Present At JPMorgan Healthcare Conference
1/4/2006
-
Debiopharm S.A. And Dyax Corp. Restructure Development Agreement For DEPELESTAT In Pulmonary Disorders
12/20/2005
-
Dyax Corp. Announces Key Management Team Promotions
12/9/2005
-
Dyax Corp. And Genzyme Corporation Initiate Pivotal Phase III Trial Of Subcutaneously Administered DX-88 For The Treatment Of Hereditary Angioedema
12/8/2005
-
Dyax Corp. Announces Third Quarter Financial Results; HAE program On Track To Begin Phase III Trial Before Year End; R&D
10/26/2005
-
Antibodies Derived From Dyax Corp. Library Enter Clinical Trials At ImClone Systems
1/11/2005
-
The Day In Review: Biotech Outpaces Market As A Whole
1/10/2005